Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($0.82), $0.11 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $51.3 million versus the consensus estimate of $51.02 million.

Financial Guidance: Today, Rhythm updated its financial guidance for the year ending December 31, 2025. The Company anticipates approximately $295 million to $315 million in Non-GAAP Operating Expenses. Non-GAAP Operating Expenses are derived from:

GAAP total operating expenses, inclusive of

SG&A expenses of approximately $145 million to $150 million;
R&D expenses of approximately $150 million to $165 million; and
Excluding stock-based compensation.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.